Alphav Beta6 Integrin Expression in Inflamed & Malignant Prostate by Hackett, Melissa Christine
Worcester Polytechnic Institute
Digital WPI
Major Qualifying Projects (All Years) Major Qualifying Projects
April 2006
Alphav Beta6 Integrin Expression in Inflamed &
Malignant Prostate
Melissa Christine Hackett
Worcester Polytechnic Institute
Follow this and additional works at: https://digitalcommons.wpi.edu/mqp-all
This Unrestricted is brought to you for free and open access by the Major Qualifying Projects at Digital WPI. It has been accepted for inclusion in
Major Qualifying Projects (All Years) by an authorized administrator of Digital WPI. For more information, please contact digitalwpi@wpi.edu.
Repository Citation
Hackett, M. C. (2006). Alphav Beta6 Integrin Expression in Inflamed & Malignant Prostate. Retrieved from
https://digitalcommons.wpi.edu/mqp-all/1653
 i 
MQP-BIO-DSA-4133 
 
 
αvβ6 Integrin Expression in Inflamed & Malignant Prostate 
 
A Major Qualifying Project Report 
Submitted to the Faculty of the 
WORCESTER POLYTECHNIC INSTITUTE 
in partial fulfillment of the requirements for the 
Degree of Bachelor of Science  
in 
Biology and Biotechnology 
 
by 
 
_________________________ 
Melissa Coonradt 
 
 
April 27, 2006 
 
 
APPROVED: 
_________________________   _________________________ 
Lucia Languino, Ph.D.    David Adams, Ph.D. 
Cancer Biology     Biology and Biotechnology 
University of Massachusetts Medical School  WPI Project Advisor 
Major Advisor 
 ii 
ABSTRACT 
 
 
 Prostate cancer cell functions are regulated by elaborate signaling pathways 
activated by extracellular stimuli.  The integrin family of cell surface receptors is known 
to activate intracellular pathways in response to signals generated via specific interactions 
with the extracellular matrix.  Through the use of immunohistochemistry (IHC) and 
immunoblotting, this study shows that the αvβ6 integrin is predominately expressed in 
epithelial cells in human preneoplastic, prostate intraepithelial neoplasia (PIN), 
proliferative inflammatory atrophy lesions (PIA) and prostatic adenocarcinoma.  The 
results indicate that αvβ6 is highly expressed in areas with infiltrating leukocytes, and is 
expressed focally in malignant and some benign prostate glands, but not in normal 
prostate tissue. 
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BACKGROUND 
 
Prostate Cancer 
With the exception of skin cancer, prostate cancer is the most commonly 
diagnosed form of cancer in American men.  It is estimated that 1 in 6 men will be 
diagnosed with this form of cancer at some point during his lifetime, although with early 
detection and treatment only 1 in 34 will die from it (http://www.cancer.org/).  The 
American Cancer Society estimates that 232,090 men will be diagnosed with prostate 
cancer in 2005 alone.  Despite treatment options and the benefits of early detection, 
prostate cancer is exceeded only by lung cancer as the leading cause of death among men 
in the United States, accounting for nearly 10% of all cancer-related deaths in men.  In 
2005 it was estimated that more than 30,000 would die from prostate cancer.  The 
number of prostate cancer-related deaths remains high, but modern methods for detection 
and treatment have led to more effective therapy and thus a decline in death rate of nearly 
3.5% per year (http://www.cancer.org/).   
After a patient has been diagnosed and the tumor is staged according to a Gleason 
Score (Gleason, 1966) there are several options available for treatment: expectant 
management, surgery to remove the entire prostate and some surrounding tissue, 
radiation therapy, cryosurgery, androgen deprivation therapy, chemotherapy, treatment 
only for pain and other symptoms, or clinical trials (http://www.nccn.org).  A successful 
therapeutic approach has not been identified making it likely that the cancer will 
metastasize to another area of the body.  Ideally, a patient would have several options for 
treatment, each promising a future without ongoing tumor therapies.  Doctors and 
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researchers are working to improve detection, diagnosis and treatment for prostate 
cancer, while exploring ways to prevent a tumor from ever occurring.  Over the years 
many helpful discoveries have been made in this field, though there is still much that 
remains to be understood about how prostate cancer works before it can be cured or 
prevented.   
Despite many theories, scientists have not pinpointed the exact cause of prostate 
cancer.  Researchers have identified some risk factors, including lifestyle and diet.  
Several studies have indicated that a diet rich in animal fat can increase a man’s chances 
of developing prostate cancer (Bairati et al., 1998).   It has also been hypothesized that 
high levels of testosterone may lead to an increase in a man’s risk of prostate cancer 
(Gann et al., 1996).   
Prostate cancer development proceeds through a series of states that can be clearly 
defined.  Of those marked states of progression, some of the most clearly defined are 
prostatic intraepithelial neoplasia (PIN), invasive cancer, and androgen-dependent or 
androgen-independent metastases (Scher and Heller, 2000; Nicholson and Theodorescu, 
2003).  Accumulating data suggest that an inflammation-carcinoma sequence has been 
invoked as a potential mechanism with regard to prostate carcinogenesis (Boudreau et al., 
1995; Ruoslahti, 1997; Varner and Cheresh, 1996; Bogenrieder and Herlyn, 2003, 
Fornaro et al., 2001).  Available data are consistent with the view that proliferative 
inflammatory atrophy (PIA), which shows a low apoptotic rate, may represent a precursor 
of high-grade PIN or prostate cancer (DeMarzo et al., 1999).   
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Integrin and Integrin Functions 
Integrins are a group of heterodimeric transmembrane glycoproteins responsible 
for cell to cell interactions, as well as cell to extracellular matrix (ECM) interactions, and 
the modulation of a variety of cellular functions (Hynes, 2002).  Their function is 
regulated at many levels, though the ligand specificity of a given integrin depends on 
which α-chain associates with 
which β−chain (Figure 1).  All 
human cells express one or more 
of the integrin heterodimers, with 
the exception of erythrocytes 
(Hynes, 1992).  Integrins are 
important for the alteration of 
cellular growth and tumor 
progression through the 
regulation of apoptosis, cell 
adhesion, proliferation, gene 
expression and migration (Breuss 
et al., 1995).  The variety of integrin functions is also what allows these cation-dependent 
receptors to control events that lead to malignant tumor growth (Fornaro et al., 2001).  
Each is made up of one α subunit non-covalently bound to a β subunit (Busk et al., 
1992).  Every integrin must have both subunits to be expressed on the cell surface.  
Without either than alpha or beta chain, the single subunit will be degraded before 
Figure 1. Integrin Structure (http://www.aw-bc.com/) 
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reaching the surface.  To date, 18 α subunits and 8 β subunits have been found, for a total 
of 24 complexes that have been identified, with expression and function being 
characterized in a variety of cell types (Fornaro et al., 2001).  In prostate cancer, tumor 
cells have a different surrounding matrix than normal cells; thus changes in the integrin 
profile may be functionally relevant and contribute to metastases establishment and 
growth (Bogenreider and Herlyn, 2003; Fornaro et al., 2001).  A number of studies have 
reported changes in integrin expression profile as prostate cancer progresses to an 
advanced stage (Knox et al., 1994; Murant et al., 1997).  This project focuses on the 
integrin αvβ6, a member of the integrin family of transmembrane protein receptors which 
mediate attachment of cells to the ECM through the binding of ligands such as latency-
associated peptide (LAP) of transforming growth factor-β (TGF-β) (Munger et al., 1999), 
fibronectin (Busk et al. 1992), tenascin (Prieto et al., 1993) and vitronectin (Huang et al., 
1998).  αvβ6 is detectable exclusively in epithelial cells and observed primarily during 
embryonic development.  In fully differentiated epithelia αvβ6 is barely detectable, but is 
strongly induced during wound healing, inflammation and tumorigenesis  (Breuss et al., 
1995).  αvβ6 is frequently up-regulated in epithelial tumors.  Research has shown the up-
regulation of αvβ6 in lung (Smythe et al., 1995), breast (Arihiro et al., 2000), colon 
(Agrez et al., 1994), colorectal (Bates, 2005), oral (Regezi et al.,  2002), ovarian (Ahmed 
et al., 2002) and pancreatic cancer (Sipos et al.,  2004).  A connection has also been 
identified between αvβ6 and metastasis in oral squamous cell carcinoma (Busk et al., 
1992; Breuss et al., 1995; Jones et al., 1997) and ovarian cancer (Ahmed et al., 2002).  
Despite expression of αvβ6 in these forms of cancer, it is still not entirely understood 
how αvβ6 may influence tumor formation and metastasis.      
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Integrins in Wound Healing 
 Wound repair is one of the most important aspects of skin maintenance, 
involving complex interactions between the epidermis, dermis and immune cells 
(Hakkinen et al.,  2004).  To prevent infection, a wound must be covered as quickly as 
possible.  This process, known as re-epithelialization, involves epidermal cells from the 
area immediately surrounding a wound.  Once in place, epidermal cells can begin 
dividing and proliferating to cover the injured area.  Integrins are an important factor in 
this process, as they facilitate the migration of epidermal cells, and contribute to cell-to-
ECM or cell-to-cell interactions (Hakkinen et al., 2000).  Integrins are able to affect cell 
motility because of their affinity for a given ligand, such as fibronectin and laminin.  An 
integrin’s affinity for a ligand is not particularly strong, which means that several 
integrins must be localized at a focal contact in order to form an effective cell-to-cell or 
cell-to-ECM contact.  An integrin expressed equally over the entire cell surface or a 
region of the cell surface will not attract its ligand (Cohen et al., 2004).  Human 
epidermal cells have the ability to synthesize eight integrins capable of mediating cellular 
responses to ECM molecules (Larjava et al., 1996).  For example, the integrin α6β4 is 
seen in epidermal cells that are bound to the basement membrane, though it facilitates 
cell migration after injury when distributed over the entire cell surface, as opposed to 
being focally expressed on the lower region of epidermal cells (Stepp et al., 1990).  In 
addition to the normally expressed integrins, there are integrins that only appear during 
wound repair.  For example, integrin α5β1 can be observed a short time after wounding 
and lasts only a few hours before it can no longer be detected at the wound site (Larjava 
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et al., 1993).  Finally, as epidermal cells undergo re-epithelialization, the basement 
membrane is formed and the fusion of newly formed epidermal sheets is associated with 
higher levles of the integrin αvβ6.  The molecule is a binding partner of some wound 
matrix molecules, although it is not involved with epidermal cell migration, as can be 
demonstrated by the fact that it appears in the later stages of wound repair after cell 
migration has stopped (Koivisto et al., 1999).   
 
Inflammation and Cancer 
 
 It has long been accepted that chronic inflammation can lead to some types of 
cancer.  Most commonly, chronic inflammation of the gastrointestinal tract is associated 
with colon and / or colorectal cancer (Dalgleish and O’Byrne, 2006).  In 1863 Rudolf 
Virchow first noted leukocytes in 
neoplastic tissue, making a 
connection between inflammation 
and cancer.  He hypothesized that 
the origin of cancer was at the site 
of chronic inflammation, and that 
some irritants, when combined with 
tissue injury and the resulting 
inflammation would result in the 
enhancement of cell proliferation 
(Coussens and Werb, 2002).  Current research supports Virchow’s findings, as scientists 
seek to further understand the inflammatory microenvironment of malignant tissues 
Table 1: Some associations between inflammation 
and cancer risk (Balkwill and Mantovani, 2001). 
  
Malignancy Inflammatory stimulus / condition 
Bladder Schistosomiasis 
Cervical Papillomavirus 
Ovarian Pelvic Inflammatory Disease / talc / 
tissue remodeling 
Gastric H. pylori induced gastritis 
MALT lymphoma H. pylori 
Oesophageal Barrett’s metaplasia 
Hepatocelluar Hepatitis virus (B and C) 
Bronchial Silica, asbestos, cigarette smoke 
Mesothelioma Asbestos 
Kaposi’s sarcoma Human herpesvirus type 8 
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(Balkwill and Mantovani, 2001).  Above is a table taken from Balkwill and Mantovani’s 
review article titled “Inflammation and cancer: back to Virchow?”.  The authors cite an 
article which suggests that 15% of the global cancer burden can be attributed to infectious 
agents, of which inflammation is a major component.  Balkwill and Mantovani also 
suggest that an increased risk of malignancy can be associated with chronic inflammation 
as a result of chemical and physical agents as well as autoimmune disorders and 
inflammatory reactions of uncertain etiology.   
 In order to understand how inflammation can lead to the formation of cancer, one 
must understand how inflammation functions and its contribution to both physiological 
and pathological processes such as wound healing and infection.  In addition to the 
section above involving wound healing and integrins, there is the immune aspect of 
wound repair, which involves the activation and directed migration of leukocytes such as 
neutrophils, monocytes and eosinophils from the circulatory system to the wounded area.  
In a review article titled “Inflammation and Cancer” (2002) by Coussens and Werb,  the 
authors explain how inflammatory cells are recruited to a wound where they form a 
provisional ECM, creating a base for fibroblasts and endothelial cells to proliferate, thus 
restoring the normal microenvironment of the skin.     
 In addition to the mechanism for recruitment of inflammatory cells is a family of 
chemotactic cytokines known as chemokines.  Chemokines are able to attract specific 
leukocyte populations and have the ability to control the inflammatory response.  Tumor 
necrosis factor-α and TGF-β1 are two proinflammatory cytokines that have the ability to 
control inflammatory cell populations and mediate other aspects of inflammation 
(Coussens and Werb, 2002).  Generally speaking, normal inflammation is self-limiting, 
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that is, anti-inflammatory cytokines are active shortly after pro-inflammatory cytokines, 
preventing the continued recruitment of inflammatory cells to the site of a wound.  Any 
disruption in this process can result in abnormalities and eventually pathogenesis.  
Although there is evidence showing inflammation contributing to several types of cancer, 
as seen in Table 1, there 
is no evidence supporting 
a role for inflammation in 
prostate cancer 
progression.  It has been 
hypothesized that PIA 
contributes to progression 
from preneoplastic to 
neoplastic phenotype in 
prostate, as shown in 
Figure 2.   
 
 
 
 
 
 
 
 
Figure 2.  Progression of normal prostate epithelium into 
cancer when influence by inflammatory cells. 
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PROJECT PURPOSE 
 
 
For this project one specific cell surface integrin receptor, αvβ6, was examined to 
confirm its presence in malignant prostate tissue, as well as to explore the molecule’s 
possible function as a regulator mediating the prostate cancer progression.  Results 
obtained through immunoblotting and immunohistochemistry show that αvβ6 is 
predominantly expressed in PIN, PIA, and adenocarcinoma in human prostate cancer 
tissue. 
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METHODOLOGY 
 
 
Antibodies 
 The following antibodies were used in this project: anti-human β6 integrin, 2A1 
(Biogen Idec, Inc., Cambridge, MA) for immunohistochemical (IHC) staining, purified 
anti-mouse IgG (mIgG) or anti-rabbit IgG from Pierce (Rockford, IL); anti-Akt from Cell 
Signaling (Beverly, MA); and anti-β6 integrin (B1) (a gift from Dr. Dean Sheppard, 
UCSF, San Francisco, CA).   
 
Cells and Culture Conditions 
 RWPE-1 and LNCaP cells were purchased from ATCC.  LNCaP stable cell lines 
expressing full-length β6 integrin.  RWPE-1 cells were cultured in a defined keratinocyte 
serum free medium supplemented with pituitary extracts, 100 units/ml penicillin and 100 
µg/ml streptomycin (all from GIBCO, Invitrogen, Grand Island, NY).  LNCaP cells were 
cultured in RPMI 1640 (Invitrogen) containing 10% fetal bovine serum (FBS) (Gemini 
Bio-Products, Woodland, CA), 100 units/ml penicillin, 100 µg/ml streptomycin, 292 
µg/ml L-glutamine, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate and 1 mM 
HEPES (all from Invitrogen).  Transfected LNCaP cells were cultured in the same 
medium as LNCaP cells with 1 mg/ml G418 (Invitrogen). 
 
Human Tissue Specimens 
 Specimens from 48 human radical prostatectomies performed for prostatic 
adenocarcinoma from the Cooperative Human Tissue Network (CHTN) (Vanderbilt 
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University, Nashville, TN) and the Department of Pathology, University of 
Massachusetts Medical School (Worcester, MA) were processed according to Review 
Board – approved protocols.  Tissues were fixed in neutral-buffered formalin and 
embedded in paraffin.  Hematoxylin and eosin sections were reviewed, and the tumor 
grade, according to Gleason’s criteria (Gleason, 1966) and the stage of tumor, according 
to TNM system (Sobin, 1997) were estimated in each tumor sample.   
 
Immunoblotting 
 Cells were lysed in lysis buffer containing 20 mM Tris pH 7.5, 150 mM NaCl, 
10% glycerol, 1% NP-40, 10 mM NaF, 1 mM NaVO4, 1 mM Na4O7P2, 2 µM leupeptin, 
2 µM aprotinin, and 1 mM phenylmethylsulfonyl fluoride (PMSF).  Cell lysates were 
cleared by centrifugation at 14,000 rpm for 15 minutes at 4°C, and total protein was 
quantified using a BCA Protein Assay (Pierce Biotechnology, Inc, Rockford, IL).  Total 
protein was resolved by SDS-PAGE, transferred onto PVDF membranes, and 
immunoblotted with pAb to Akt (0.1 mg/ml), mAb to β6 integrin (1:10).  Proteins were 
visualized using ECL reagent and developed using autoradiography (Kodak X-Omat AR 
film). To determine Akt activation in β6 LNCaP cells, cells were serum starved for 12 hr 
and plated on mIgG (2.5 µg/ml), β6 integrin antibody 10D5 (2.5 µg/ml), BSA (1%), or 
LAP-TGF-β (0.5 µg/ml) coated 60 mm plates at the density of 1 X 10
6
 cells per plate.  
After incubation for 30 min or 1 hr, cells were lysed in a lysis buffer containing 20 mM 
Tris pH 7.5, 150 mM NaCl, 10% glycerol, 1% NP-40, 10 mM NaF, 1 mM NaVO4, 1 mM 
Na4O7P2, 2 µM leupeptin, 2 µM aprotinin, and 1 mM phenylmethylsulfonyl fluoride  
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(PMSF).  Proteins (50 µg) were separated by 10% SDS-PAGE under reducing conditions 
and immunoblotted with an Ab specific to Akt as a loading control. 
 
Immunohistochemistry (IHC) 
 
 All IHC staining was performed on 4 µm sections prepared from paraffin-
embedded blocks and placed on charged glass slides. The sections were first 
deparaffinized in two changes of xylenes, and then rehydrated in ethanol and distilled 
water.  For β6 integrin staining, the sections were incubated in 3% hydrogen peroxide 
(H2O2) in methanol to remove endogenous peroxidase activity.  Antigen retrieval was 
performed by incubating the sections with pepsin at 37°C for 5 min.  Following two 
washes in PBS, the slides were blocked for biotin activity with Avidin/Biotin Blocking 
Kit (Vector) at room temperature. After rinsing, the sections were blocked with 0.25% 
casein (SP 5020,Vector Laboratories) in PBS for 15 min at room temperature and then 
incubated with primary antibody overnight at 4°C.  Human prostate sections were stained 
with 0.5 µg/mL mouse mAb 2A1 (Biogen Idec, Inc., Cambridge, MA) . A mouse-IgG, 
0.5 µg/ml in 1% BSA in PBS, was substituted for the antibody as negative control.  After 
washing with PBS, the biotinylated secondary IgG antibody was applied for 30 min at 
room temperature.  Immunoperoxidase staining was performed using the Vectastatin 
Elite ABC kit (6200 Vector kit for human prostate tissue; Vector Laboratories, Inc., 
Burlingame, CA).  The signal was amplified using DAB Substrate-Chromogen System 
(K0367, Dako Cytomation).  Finally, the slides were counterstained with Mayer’s 
hematoxylin and dehydrated.  Tissue sections were examined on an Olympus BX41 
microscope and photographed using an Olympus DP12 camera. The immunostaining 
results were independently evaluated by Dr. Z. Jiang, Dr. L.R.Languino, and Dr. J.Li 
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(University of Massachusetts Medical School Departments of Pathology and Cancer 
Biology) and scored in two classes by percentage (positive “+” and negative “-“ 
immunoreactivity) of glands over the total glands of tissue. 
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RESULTS & ANALYSIS 
 
 
Immunoblotting Analysis of β6 Expression in Human Tissue Lysates 
 Immunoblotting analysis of β6 subunit expression in benign and tumor prostate 
tissue as well as RWPE cell lysate and non-tumorigenic LNCaP prostate cells was 
performed.  It is important to also note that detection of the β6 subunit includes the 
presence of αv, as β6 is only able to bind αv.  Without the alpha subunit, β6 would be 
degraded.  Therefore, where it is stated that β6 is present one can assume αv is also 
present.  Results obtained using 2A1 monoclonal antibody (mAb) against β6 showed 
expression of the β6 subunit at 90-110 kDa under non-reducing conditions for both 
benign and malignant prostate tissue (Figure 3).  RWPE-1 cells, which are known to 
express αvβ6 integrin shows strong β6 expression using 2A1 mAb under non-reducing 
conditions.  RWPE-1 was used as a positive control for all immunoblot analysis.  Non-
tumorigenic LNCaP cells do not express αvβ6, as demonstrated in Figure 3 (lane 11) 
where no expression can be seen in the lane containing 20 µg of LNCaP lysate.  These 
findings show that β6 is expressed in both tumor and benign prostate tissue.  Later, 
unpublished, findings revealed that αvβ6 is not present in normal prostate tissue.  When 
combined with the evidence of strong β6 expression in the presence of infiltrating 
leukocytes (Figure 5), it is possible that the expression of β6 in immunoblotting is the 
result of leukocytes in the tissue lysates.  Given the distribution of β6 observed in 
immunostained sections of prostate (shown in subsequent figures) it is difficult to analyze 
the results shown in Figure 3.  As a result, the information obtained in Figure 3 is strictly 
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verification that the 2A1 antibody does, in fact, specifically bind a protein of the correct 
size.   
 
 
Expression of Integrin αvβ6 in Human Prostate Tissue 
 In addition to the results obtained through immunoblotting, we were able to show 
the focal expression of β6 at sites of inflammation (Figure 5), proliferative inflammatory 
atrophy (PIA) and prostate intraepithelial neoplasia (PIN) in benign and malignant 
specimens (Figure 4).  Strong reactivity was observed in malignant prostate sections 
stained with monoclonal 2A1 antibody against the β6 integrin subunit (Figure 4A).  The 
specificity of the 2A1 antibody was verified using β6-transfected SW480 cells, shown in 
Figure 4C, when compared with the negative control (Figure 4D) stained with mouse 
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IgG.  No expression of β6 was observed in normal human prostate tissue obtained from a 
biopsy (Figure 4E).  The β6 subunit was found to be focally expressed in benign tissue 
sections, that is, areas of “normal” tissue within a pathogenic prostate (Figure 4F).   
 
 
Strong immunoreactivity was consistently observed in glandular tissue surrounded by 
inflammatory cells (Figure 5). The expression of β6 in these areas appeared to be cell-
type specific, as it was observed in epithelial cells but not in stromal cells or the 
infiltrating inflammatory cells.  Based on the above results, the conclusion is that αvβ6 
expression is inducible in adenocarcinoma tissue while normal tissue shows little 
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expression.  Additionally, β6 expression can be detected in response to cancer-associated 
lesions of inflammation, PIA and PIN.   
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DISCUSSION 
  
 Prostate cancer cell functions are regulated by elaborate signaling pathways 
activated by extracellular stimuli.  The integrin family of cell surface receptors is known 
to activate intracellular pathways via interactions with specific ligands in the tumor 
microenvironment.  Among others, the αvβ6 integrin appears to be a key player in 
mediating cancer progression given its ability to mediate signals originating in the tumor 
microenvironment via activation of latent TGF-β.  An increasing amount of data suggests 
that the expression of αvβ6, which is not typically found in the healthy adult, is 
associated with neoplastic and metastatic phenotypes in colorectal, lung, oral, ovarian, 
breast, and pancreatic cancers.  Research for this project focused on the expression of β6 
(a subunit of the αvβ6 heterodimer) in human prostate cancer tissue specimens.  Results 
show that while αvβ6 is not expressed in normal human prostate, it is induced in human 
prostatic intraepithelial neoplasia (PIN), proliferative inflammatory atrophy (PIA) and 
prostatic adenocarcinoma.   
 The research done for this project is only a small portion of the entire report being 
compiled for publication, which ultimately found that αvβ6 regulates survival and 
proliferative pathways, and consequently, prostate tumor growth, via modulation of AKT 
and androgen receptor activity.  My work on this project helped lead the lab to the 
finding that integrins inhibit androgen receptor activity, suggesting a novel integrin-
mediated mechanism of prostate cancer progression.  In addition to my analysis with 
prostate tissue using immunohistochemistry, later work was done in mice to show that the 
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expression of αvβ6 in LNCaP prostate cancer cells results in increased tumor volume in 
SCID mice, as compared to expression of a different αv−containing integrin αvβ3.  
Further analysis of the mechanism by which αvβ6 increases tumor growth shows that it 
inhibits androgen receptor transcriptional activity via activation of the PI3-kinase/AKT-
pathway.  Additionally, results show that αvβ6 inhibition of androgen receptor (AR) 
activity results in up-regulation of an anti-apoptotic molecule, survivin, known to 
promote prostate cancer progression and radio/chemo-resistance (unpublished data).  The 
above findings have important implications for prostate cancer therapy, since altered AR 
activity is believed to be the main contributing factor leading to the development of 
prostate cancer.  Understanding of an αvβ6-mediated signaling pathway which controls 
AR activity is therefore important in understanding the molecular mechanism leading to 
prostate cancer progression.  The future direction of this project will be to determine what 
induces αvβ6 in the prostate.  This will be done through the screening of a number of 
cytokines to find which ones have the ability to up-regulate the expression of αvβ6 in 
prostate cell lines.  Ultimately, the goal is to find what causes increased inflammation in 
the prostate, which may be a precursor to prostate malignancies and then to find a way to 
prevent the inflammation from occurring, theoretically preventing some forms of prostate 
cancer from ever developing.  
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